European review for medical and pharmacological…
2016
OBJECTIVE
MiR-183 acts as an oncomiR and is usually upregulated in hepatocellular cancer (HCC). This study aims to study the association between miR-183 dysregulation and multi-drug resistance (MDR).… (More)